Electronic Cigarette or Vaping-associated Lung Injury (EVALI): The Tip of the Iceberg

Suhny Abbara, MD, FACR, MSCCT • Fernando Uliana Kay, MD, PhD

From the Department of Radiology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9316. Received October 4, 2019; revision requested October 8; revision received October 10; accepted October 11. Address correspondence to S.A. (e-mail: sabbara@rsna.org).

Several authorities, including the Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration, and state and local health departments, have started an investigation into the perceived widespread outbreak of lung injury attributed to the use of electronic cigarette (e-cigarette) or vaping products, or EVALI. The CDC has been monitoring the number of cases reported since March 2019. As of October 15, 2019, 1479 cases have been reported to the CDC from 49 states, the District of Columbia, and one U.S. territory, of which 33 have resulted in death (1). However, these numbers likely underestimate the true incidence and prevalence of disease due to lack of recognition and reporting of vaping-associated lung injury.

E-cigarettes act by delivering nicotine, flavorings, and other additives in aerosol form (2). They were introduced in the United States around 2007 and since 2017 are the most commonly used form of tobacco among U.S. youths (2). In fact, some vaping products are so popular among teenagers that they have resulted in the coining of new words. For example, JUULing refers to the use of the e-cigarette brand JUUL, which looks like a USB memory stick and is easily concealed. Another new verb used by teenagers for the use of electronic nicotine delivery systems is ripping.

Since 2012, several cases reported in the literature have raised the awareness of the potential link between e-cigarette use and lung injury (3–9). A recently published case series of lung injury associated with e-cigarette use in the states of Illinois and Wisconsin (10) identified 53 individuals meeting case criteria. There was one death among the cases. Most of the patients in this series were male (n = 44, 83%), with an overall median age of 19 years (age range, 16–53 years). Fifty-two patients (98%) presented with respiratory symptoms, which were present for a median duration of 6 days before hospitalization. Common respiratory symptoms included shortness of breath (n = 46, 87%), cough (n = 44, 83%), and chest pain (n = 29, 55%). Fever was noted in 29% of the cases (n = 15) at presentation. Tachycardia and tachypnea were also commonly noted (n = 34 and 22, 64% and 43%, respectively). Elevated white cell count was seen in 45 cases (87%), with an interquartile range of values between 12.30 and 18.10 × 10^9/L. About 45% of the patients (n = 24) were given empirical antibiotic therapy for presumed respiratory infection. Prevalence of imaging findings is confounded by the epidemiologic definition of a case; notwithstanding, opacities were noted to involve both lungs in all cases. Forty-eight of the 53 patients also underwent chest CT; ground-glass opacities with pleural sparing were characteristically found. Complications such as pleural effusions, pneumothorax, and pneumomediastinum occurred in eight of the 48 patients who underwent CT. Basilar predominance also seems to be a frequent feature (11).

However, these cases are by no means comprehensive, and the publicly available data may represent only the tip of the iceberg. Additionally, the long-term effect of decades’ worth of use of electronic nicotine delivery systems on the lungs and other organ systems is unknown. This special report aims to raise awareness of the presentation of vaping-associated lung disease. We illustrate some of the radiographic and CT findings of lung injury with a clinical case of a 24-year-old male patient with past medical history of asthma, who presented with shortness of breath, productive cough, chest pain, and fever for 1 week. He reported current everyday use of e-cigarettes (with tobacco) and marijuana, without substantial change in recent vaping habits. He had a white cell count of 18.1 × 10^9/L (normal reference [NR], 4.2–10.3 × 10^9/L) and a platelet count of 464 × 10^9/L (NR, 160–383 × 10^9/L). His chest radiograph on admission is shown in Figure 1.

The radiologic findings included bilateral basilar predominant ground-glass and reticular opacities with smaller areas of consolidation. The patient was given...
empirical antibiotic therapy with standard dose of azithromycin for a presumptive diagnosis of pneumonia. Test results for human immunodeficiency virus and respiratory viruses were negative. Chest CT angiography was performed on the following day for exclusion of pulmonary embolism given the lack of clinical improvement with the empirical treatment and elevated D-dimer level (0.54 μg/mL, NR ≤ 0.50 μg/mL) (Fig 2).

The study was negative for pulmonary embolism; pulmonary findings included several differential diagnoses, such as acute interstitial pneumonia and diffuse alveolar damage. Sputum and blood cultures were negative. The rheumatologic panel result was unrevealing. Histologic specimens obtained from the right lower lobe at transbronchial biopsy revealed positive staining for lipid by Oil Red O, suggestive of lipoid pneumonia. The patient was given steroids with a presumptive diagnosis of lung injury associated with e-cigarette use.

Currently, the epidemiologic case definition of lung injury associated with e-cigarette use for surveillance purposes includes the presence of all of the following criteria: (a) use of e-cigarette or dabbing (butane hash oils) within 90 days before symptom onset; (b) presence of pulmonary opacities on chest radiographs or ground-glass opacities on chest CT images; (c) absence of pulmonary infection at initial workup; and (d) no evidence of alternative plausible diagnoses (1). The case report exemplified in this article shares many of the clinical and radiologic features found in the Wisconsin and Illinois cases series (10,11). The combination of acute respiratory symptoms with fever and leukocytosis initially raised the suspicion for infection, which was subsequently excluded on further examination. Imaging findings on the chest radiograph were nonspecific, consisting of bilateral and basilar predominant opacities, which were further confirmed to represent a combination of ground-glass opacities and consolidation at CT. Interestingly, we also observed relative preservation of the subpleural regions of the lungs, a feature identified by Henry et al in the Wisconsin and Illinois series (11). It is plausible to hypothesize that such a phenomenon could be related to the main involvement of the central aspect of the secondary pulmonary lobule, as this is believed to represent a response to an inhaled agent.

The pathophysiology of vaping-associated lung injury remains unknown. According to data collected by the CDC, most cases reported exposure to cannabinoid products (tetrahydrocannabinol and cannabidiol), although some cases have reported nicotine exposure alone (1). Prior reports have directly linked the inhalation of derivatives of marijuana to acute lung injury (5,12,13). These cases clinically manifested with acute respiratory distress and hemoptysis. At least in one case, bronchoscopy results revealed diffuse alveolar hemorrhage and organizing pneumonia (5). Many other elements found in e-cigarette products have also been found to pose potential health risks (14). Lipids present in aerosols derived from e-cigarettes could play a role in the development of lipoid pneumonia (15,16). On September 5, 2019, the New York State Department of Health announced the discovery of high vitamin E acetate concentrations in cannabis-containing samples of vape products submitted for testing, which is a nonapproved additive according to state regulations (17). In a recent series of six patients from the state of Utah, Maddock et al (16) underscored the consistent finding of lipid-laden macrophages stained by Oil Red O in the bronchoalveolar lavage, with numbers ranging from 25% to more than 75% of the sample. In another study, Burt et al (18) reviewed the pathologic slides of a series of 17 patients from the Mayo Clinic Network meeting epidemiologic criteria for vaping-related lung injury according to the CDC. Although accumulation of foamy macrophages centered in the airways with vacuolization of type 2 pneumocytes was an omnipresent finding, diverse patterns were seen at histology, including acute fibrinous pneumonitis, diffuse alveolar damage, organizing pneumonia, interstitial edema, intra-alveolar fibrin, and reactive type 2 pneumocyte hyperplasia. In contrast to prior articles, the authors did not find
direct histopathologic evidence of exogenous lipoid pneumonia in the specimens, raising question about the potential causative role of lipids. Radiologically, cases of vaping-related lung injury resemble lipoid pneumonia, consisting of bilateral ground-glass opacities or consolidations in a segmental or lobar distribution, predominantly distributed in the middle and lower lobes (19). Although classic cases are expected to show low CT numbers within the opacities (eg, −30 HU), this appearance can be confounded by the presence of inflammation and differences in the amount of exogenous lipoid material. Current CDC recommendations state that, when obtained, bronchoalveolar lavage and fresh biopsy specimens should be subject to lipid staining (1).

Radiologists will continue to play an important role in recognizing this emerging entity. This diagnosis should be listed as a differential possibility in patients presenting with bilateral lung opacities on radiographs or ground-glass opacities on chest CT images and exposure to e-cigarette products within 90 days of the presentation. Subpleural sparing and basilar consolidation appear to be common features. It is crucial that radiologists drive some of the research initiatives to better understand the mechanisms of disease presentation, facilitating the diagnosis and management of these patients. These efforts should be done as a team effort with other specialties, including pathologists, epidemiologists, pulmonologists, and emergency physicians. We encourage the medical imaging community to produce scientific evidence and medical knowledge to help us understand the value of clinical, laboratory, and imaging criteria for the diagnosis and treatment of the disease, to help advance our collective knowledge about the effects of e-cigarette use on the lungs and other organ systems.

Author contributions: Guarantor of integrity of entire study, S.A.; study concepts/study design or data acquisition or data analysis/interpretation, S.A., F.U.K.; manuscript drafting or manuscript revision for important intellectual content, S.A., F.U.K.; approval of final version of submitted manuscript, S.A., F.U.K.; agrees to ensure any questions related to the work are appropriately resolved, S.A., F.U.K.; literature research, S.A., F.U.K.; clinical studies, S.A.; and manuscript editing, S.A., F.U.K.

Disclosures of Conflicts of Interest: S.A. Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: institution receives grant from CIPRIT; author receives royalties from Elsevier for authoring textbooks. Other relationships: disclosed no relevant relationships. F.U.K. disclosed no relevant relationships.

References


2. U.S. Department of Health and Human Services, Office of the Surgeon General. E-Cigarette Use Among Youth and Young Adults: A Report of
Vaping-associated Lung Injury

